TY - JOUR
T1 - Research Advances in Mast Cell Biology and Their Translation Into Novel Therapies for Anaphylaxis
AU - Dispenza, Melanie C.
AU - Metcalfe, Dean D.
AU - Olivera, Ana
N1 - Funding Information:
This work was supported by the Division of Intramural Research of the National Institutes of Health and the National Institute of Allergy and Infectious Diseases , and a National Institutes of Health grant to M.C. Dispenza (grant AI143965).
Funding Information:
Conflicts of interest: M.C. Dispenza has consulted and/or participated in advisory boards for Aditum Bio, Blueprint Medicines, DAVA Oncology, Escient Pharmaceuticals, and Phylaxis Bioscience, and has received funding from AstraZeneca . The rest of the authors declare that they have no relevant conflicts of interest.
Publisher Copyright:
© 2023 American Academy of Allergy, Asthma & Immunology
PY - 2023/7
Y1 - 2023/7
N2 - Anaphylaxis is an acute, potentially life-threatening systemic allergic reaction for which there are no known reliable preventative therapies. Its primary cell mediator, the mast cell, has several pathophysiologic roles and functions in IgE-mediated reactions that continue to be poorly understood. Recent advances in the understanding of allergic mechanisms have identified novel targets for inhibiting mast cell function and activation. The prevention of anaphylaxis is within reach with new drugs that could modulate immune tolerance, mast cell proliferation and differentiation, and IgE regulation and production. Several US Food and Drug Administration–approved drugs for chronic urticaria, mastocytosis, and cancer are also being repurposed to prevent anaphylaxis. New therapeutics have not only shown promise in potential efficacy for preventing IgE-mediated reactions, but in some cases, they are able to inform us about mast cell mechanisms in vivo. This review summarizes the most recent advances in the treatment of anaphylaxis that have arisen from new pharmacologic tools and our current understanding of mast cell biology.
AB - Anaphylaxis is an acute, potentially life-threatening systemic allergic reaction for which there are no known reliable preventative therapies. Its primary cell mediator, the mast cell, has several pathophysiologic roles and functions in IgE-mediated reactions that continue to be poorly understood. Recent advances in the understanding of allergic mechanisms have identified novel targets for inhibiting mast cell function and activation. The prevention of anaphylaxis is within reach with new drugs that could modulate immune tolerance, mast cell proliferation and differentiation, and IgE regulation and production. Several US Food and Drug Administration–approved drugs for chronic urticaria, mastocytosis, and cancer are also being repurposed to prevent anaphylaxis. New therapeutics have not only shown promise in potential efficacy for preventing IgE-mediated reactions, but in some cases, they are able to inform us about mast cell mechanisms in vivo. This review summarizes the most recent advances in the treatment of anaphylaxis that have arisen from new pharmacologic tools and our current understanding of mast cell biology.
UR - http://www.scopus.com/inward/record.url?scp=85152276398&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85152276398&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2023.03.015
DO - 10.1016/j.jaip.2023.03.015
M3 - Article
C2 - 36958519
AN - SCOPUS:85152276398
SN - 2213-2198
VL - 11
SP - 2032
EP - 2042
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 7
ER -